Holen Sie sich die Stockscreener-App
42.95
0.28%
-0.12
Handel nachbörslich:
42.95
Schlusskurs vom Vortag:
$43.07
Offen:
$43.11
24-Stunden-Volumen:
1.38M
Relative Volume:
0.87
Marktkapitalisierung:
$7.94B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-11.73
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
+4.78%
1M Leistung:
-1.81%
6M Leistung:
-5.89%
1J Leistung:
+54.77%
1-Tages-Spanne:
$42.60
$44.00
1-Wochen-Bereich:
$40.22
$44.00
52-Wochen-Spanne:
$27.40
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
42.95 | 7.94B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Is Revolution Medicines, Inc. (NASDAQ:RVMD) Trading At A 49% Discount? - Yahoo Finance
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
RAS Cancer Breakthrough? Revolution Medicines CEO Takes Center Stage at Major Biotech Event - StockTitan
Revolution Medicines: New Data Underscore A True Cancer Revolution (Upgrade) - Seeking Alpha
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $66.25 Average Target Price from Analysts - MarketBeat
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround - MSN
Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials By Investing.com - Investing.com South Africa
Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials - Investing.com Canada
Revolution Medicines general counsel Jeff Cislini sells $97,443 in stock - MSN
Revolution Medicines general counsel Jeff Cislini sells $97,443 in stock By Investing.com - Investing.com Australia
Sandy Cove Advisors LLC Acquires Shares of 42,008 Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Is Revolution Medicines, Inc. (RVMD) the Best Russell 2000 Stock to Invest in According to Analysts? - Insider Monkey
Certain Restricted Stock Units of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025. - Marketscreener.com
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Revolution Medicines (NASDAQ:RVMD) Trading Down 4.6%Should You Sell? - MarketBeat
(RVMD) Trading Advice - Stock Traders Daily
Revolution Medicines, Inc. (RVMD): The Biotech Stock with Biggest Upside Potential - Insider Monkey
Revolution Medicines’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com Nigeria
Stocks Generating Improved Relative Strength: Revolution Medicines - MSN
Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, UBS Group Analyst Says - Defense World
UBS Group Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock - MarketBeat
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Principal Financial Group Inc. Trims Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World
Brokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Price Target at $65.82 - Defense World
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Revolution Medicines (RVMD) Shares Cross Below 200 DMA - Nasdaq
Revolution Medicines Becomes Oversold (RVMD) - Nasdaq
(RVMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Revolution Medicines divulges new GTPase KRAS, NRAS and HRAS inhibitors - BioWorld Online
Revolution Medicines COO Margaret Horn sells shares worth $196,553 - Investing.com India
Revolution Medicines CEO Mark Goldsmith sells $531,860 in stock By Investing.com - Investing.com Australia
Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in - EIN News
Revolution Medicines CFO Jack Anders sells shares worth $119,639 By Investing.com - Investing.com Australia
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):